Table 5.
Comparison of adverse effects between GLP-1 receptor agonists.
| Adverse reactions | Albiglutide [30] | Dulaglutide [35] | Liraglutide [22] | Exenatide QW [26] | Exenatide BID [17] | ||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| N | Albiglutide N=923, % | Placebo N=468, % | Dulaglutide 0.75 mg N=834, % | Dulaglutide 1.5 mg N=836, % | Placebo N=568, % | Liraglutide N=497, % | Exenatide N=248, % | Exenatide N=963, % | Placebo N=483, % |
| Diarrhea | 13.1 | 10.5 | 8.9 | 12.6 | 6.7 | 17.1 | 10.9 | 13 | 6 |
| Nausea | 11.1 | 9.6 | 12.4 | 21.1 | 5.3 | 28.4 | 11.3 | 44 | 18 |
| Vomiting | 4.2 | 2.6 | 6.0 | 12.7 | 2.3 | 10.9 | NA | 13 | 4 |
| Injection-site reaction or nodules | 10.5 | 2.1 | 0.5 | 0.5 | 0 | NA | 10.5 | NA | NA |